Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?

Abstract:

:Despite the recent progress in antiviral therapy of chronic hepatitis B, clinical experience has shown that antiviral drug resistance is inevitable with the administration of nucleoside analog monotherapy. The long-term persistence of the viral genome in infected cells and the high rate of spontaneous mutation is the basis for the selection of HBV mutants that are resistant to polymerase inhibitors. Selection of antiviral-resistant mutations leads to a rise in viral load and progression of liver disease. The incidence of antiviral resistance depends on the potency and genetic barrier to resistance of the antiviral drug, highlighting the importance of the choice if first line therapy. The determination of cross-resistance profile of each drug has allowed the design of rescue therapy for patients with virologic breakthrough. Early diagnosis and treatment intervention allow the majority of patients to maintain in clinical remission despite the occurrence of drug resistance. Clinical studies are ongoing to determine the best strategy to prevent or delay antiviral drug resistance and of its impact on liver disease.

journal_name

J Viral Hepat

authors

Zoulim F,Buti M,Lok AS

doi

10.1111/j.1365-2893.2007.00915.x

subject

Has Abstract

pub_date

2007-11-01 00:00:00

pages

29-36

eissn

1352-0504

issn

1365-2893

pii

JVH915

journal_volume

14 Suppl 1

pub_type

杂志文章,评审
  • Hepatitis C: What is the best treatment?

    abstract::The treatment of hepatitis C is expensive, difficult and arduous from the patient's perspective. It is similarly difficult for the clinician to decide who and when to treat. If hepatitis C is viewed from the liver's perspective we need only treat those patients who will develop the complications of chronic liver disea...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2004.00573.x

    authors: Dillon JF

    更新日期:2004-09-01 00:00:00

  • A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy.

    abstract::The risk of developing hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is reduced by antiviral therapy. Here, we evaluated the chronological trends in HCC development risk starting in 2007, when entecavir reimbursement was first initiated in South Korea. Treatment-naïve patients with chronic hepatitis B...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13384

    authors: Kim SU,Chon YE,Seo YS,Lee HW,Lee HA,Kim MN,Min IK,Park JY,Kim DY,Ahn SH,Tak WY,Kim BK,Park SY

    更新日期:2020-12-01 00:00:00

  • Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

    abstract::This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients. These fiftee...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.1996.tb00094.x

    authors: Rasi G,Mutchnick MG,Di Virgilio D,Sinibaldi-Vallebona P,Pierimarchi P,Colella F,Favalli C,Garaci E

    更新日期:1996-07-01 00:00:00

  • Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients.

    abstract::Hepatitis Be antigen (HBeAg)-negative chronic hepatitis B (CHB) is associated with hepatitis B virus (HBV) variants harbouring changes in the precore region. Most commonly, a G to A point mutation at nucleotide 1896 (m1896) creates a novel translation stop codon that prevents HBeAg production. In the Mediterranean reg...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00109.x

    authors: Laras A,Koskinas J,Avgidis K,Hadziyannis SJ

    更新日期:1998-07-01 00:00:00

  • Prevalence and impact of hepatitis B virus infection in ovarian cancer patients in an endemic area-A retrospective cohort study.

    abstract::Hepatitis B virus (HBV) infection is associated with many extrahepatic malignancies, but its association with and impact on ovarian cancer has not been examined. We therefore examined the prevalence of HBV infection among women with primary ovarian carcinoma in an endemic area, and whether this impacts the presentatio...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13250

    authors: Wong L,Cheung TH,Yim SF,Lao TT

    更新日期:2020-05-01 00:00:00

  • Visualization and characterization of GB virus-C particles: evidence for a nucleocapsid.

    abstract::GB virus type C (GBV-C) is a member of the hepacivirus genus within the Flaviviradae. Persistent GBV-C infection is common in humans, yet it remains unclear if GBV-C causes any disease. Although GBV-C infection has been associated with acute non-A to non-E post-transfusion hepatitis, it does not appear to cause chroni...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1999.00003.x

    authors: Xiang J,Daniels KJ,Soll DR,Schmidt WN,Labrecque DR,Stapleton JT

    更新日期:1999-07-01 00:00:00

  • HCV burden of infection in Egypt: results from a nationwide survey.

    abstract::Egypt is the country with the largest hepatitis C virus (HCV) epidemic in the world. In 2008, a Demographic Health Survey (DHS) was carried out in Egypt, providing for the first time a unique opportunity for HCV antibody testing on a nationwide representative sample of individuals. Consenting individuals answered a qu...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01576.x

    authors: Guerra J,Garenne M,Mohamed MK,Fontanet A

    更新日期:2012-08-01 00:00:00

  • Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.

    abstract::Viral load reduction facilitates recovery of antiviral T-cell responses. Dynamic alterations in intrahepatic viraemia clearance and immune cell reactivity during the early phase of nucleoside analogue (NA) therapy and the impact of these changes on HBeAg seroconversion are unknown. Fifteen HBeAg-positive chronic hepat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12261

    authors: Zheng Q,Zhu YY,Chen J,Liu YR,You J,Dong J,Zeng DW,Gao LY,Chen LH,Jiang JJ

    更新日期:2014-12-01 00:00:00

  • Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B.

    abstract::Quantitative serology for hepatitis B surface antigen (HBsAg) is a new candidate marker for prediction of clinical outcome. The aim of this study was to investigate the clinical significance of quantifying HBsAg in patients with hepatitis B virus (HBV) infection. A total of 424 patients who tested positive for HBsAg a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01486.x

    authors: Togo S,Arai M,Tawada A,Chiba T,Kanda T,Fujiwara K,Imazeki F,Yokosuka O

    更新日期:2011-10-01 00:00:00

  • Comparison of deaths related to Hepatitis C and AIDS in Scotland.

    abstract::In resource-rich countries, the incidence of and mortality from AIDS has fallen dramatically since the introduction of combination antiretroviral therapy. In contrast, developed countries have observed increases in the public health burden associated with the hepatitis C virus (HCV). We compared past and current trend...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00876.x

    authors: Palmateer NE,Hutchinson SJ,McLeod A,Codere G,Goldberg DJ

    更新日期:2007-12-01 00:00:00

  • Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha.

    abstract::The aim of this study was to evaluate the Chiron branched DNA (bDNA) assay for detection of serum hepatitis B virus (HBV) DNA in patients with chronic hepatitis B lacking hepatitis B e antigen (HBeAg) and undergoing interferon (IFN) therapy. Results obtained with the bDNA assay were compared with those obtained using ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00128.x

    authors: Habersetzer F,Zoulim F,Jusot JF,Zhang X,Trabaud MA,Chevallier P,Chevallier M,Ahmed SN,Sepetjan M,Comanor L,Minor J,Trépo C

    更新日期:1998-11-01 00:00:00

  • Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial.

    abstract::Patients with biopsy-proven chronic hepatitis C, who failed to respond to a previous course of either recombinant (rIFN-alpha) or lymphoblastoid (Ly IFN-alpha) interferon-alpha, were randomized to receive either leucocyte (Le) IFN-alpha (patients) or a second course of the same IFN-alpha (controls), to compare the eff...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.1997.00146.x

    authors: Gaeta GB,Di Virgilio D,Russo G,Stornaiuolo G,Nicolella U,Colella F,Grimaldi M,Pasquale G,Giusti G

    更新日期:1997-05-01 00:00:00

  • Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure.

    abstract::Chronic hepatitis B virus (HBV)-infected patients with liver failure have a poor prognosis, and no satisfactory biomarkers are available for diagnosis before the end-stage. We explored serum peptide profiling for diagnosis and prediction of progression to liver failure in HBV-infected patients. Serum samples (164) fro...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01267.x

    authors: Han T,Liu H,Yu ZL,Li J,Wang L,Xiao SX,Li Y,Yu ML

    更新日期:2010-03-01 00:00:00

  • High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.

    abstract::To determine the relationship between p53 altered expression and p53 mutations in hepatocellular carcinoma (HCC), we analysed p53 protein immunohistochemically and assessed the presence of mutations in exons 4-8 of the p53 gene using SSCP assay in 117 HCCs corresponding to 78 patients. We also determined the relations...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2004.00541.x

    authors: Anzola M,Saiz A,Cuevas N,Lopez-Martinez M,Martinez de Pancorbo MA,Burgos JJ

    更新日期:2004-11-01 00:00:00

  • Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection.

    abstract::Bacteremia has rarely been reported in patients receiving treatment for hepatitis C virus (HCV) infection. We describe the features and investigation of four cases of Staphylococcus aureus bacteremia occurring between 3 November 2004 and 10 January 2005 in patients on therapy for chronic HCV infection. The unusual occ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00828.x

    authors: Webster D,Ahmed R,Tandon P,Chui L,McDonald RR,Obarianyk A,Antonishyn N,Doucette K

    更新日期:2007-08-01 00:00:00

  • Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance.

    abstract::Seroconversion from hepatitis B surface antigen (HBsAg) to antibodies against HBsAg (anti-HBs) usually indicates resolution of hepatitis B virus (HBV) infection. Here, two HBV-infected patients with seroconversion to anti-HBs were found to be persistently positive for HBeAg and HBV DNA. Immunohistology of liver biopsi...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01322.x

    authors: Zhang ZH,Li L,Zhao XP,Glebe D,Bremer CM,Zhang ZM,Tian YJ,Wang BJ,Yang Y,Gerlich W,Roggendorf M,Li X,Lu M,Yang DL

    更新日期:2011-06-01 00:00:00

  • The role of the hepatitis viruses in cholangiocarcinoma.

    abstract::Cholangiocarcinoma is the second most common liver cancer in the world. The aetiology of the disease is diverse incorporating a variety of conditions leading to biliary stasis, biliary and liver inflammation, but a large number of cases still occur in the absence of established risk factors. Its incidence and mortalit...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12093

    authors: Ralphs S,Khan SA

    更新日期:2013-05-01 00:00:00

  • A study of hepatitis delta virus infection in patients with acute and chronic liver disease from northern India.

    abstract::To assess the prevalence of hepatitis delta virus (H delta V) in northern India, 204 adult patients with acute and chronic liver disease who were positive for hepatitis B virus (HBV) markers were screened for anti-H delta V antibody by enzyme-linked immunosorbent assay (ELISA). Anti-H delta V antibodies were positive ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1995.tb00021.x

    authors: Singh V,Goenka MK,Bhasin DK,Kochhar R,Singh K

    更新日期:1995-01-01 00:00:00

  • Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase.

    abstract::Candidate blood donors in Ghana are frequent carriers of hepatitis B virus (HBV). A comparative study of 117 donor samples including 46 with alanine aminotransferase (ALT) > or = 60 IU/L and 71 with < or =40 IU/L level was undertaken. S and the basic core promoter-precore regions (BCP/PC) sequencing was used to identi...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00741.x

    authors: Candotti D,Opare-Sem O,Rezvan H,Sarkodie F,Allain JP

    更新日期:2006-11-01 00:00:00

  • Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma.

    abstract::Approximately 30% of patients with chronic HCV infection have persistently normal ALT levels. Although formerly referred to as 'healthy' or 'asymptomatic' HCV carriers, and thus historically excluded from antiviral treatment, it has now become clear that the majority of these patients have some degree of histological ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2011.01485.x

    authors: Puoti C,Guarisco R,Spilabotti L,Bellis L,Mitidieri Costanza O,Dell' Unto O,Elmo MG

    更新日期:2012-04-01 00:00:00

  • Hepatitis delta virus propagation enabled by hepatitis C virus-Scientifically intriguing, but is it relevant to clinical practice?

    abstract::In vitro cell culture experiments and animal models have demonstrated that hepatitis delta virus (HDV) can theoretically propagate being enveloped by human pathogenic viruses other than hepatitis B virus (HBV), namely hepatitis C virus (HCV) and dengue virus. However, the clinical relevance of these findings and wheth...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13385

    authors: Pflüger LS,Schulze Zur Wiesch J,Polywka S,Lütgehetmann M

    更新日期:2021-01-01 00:00:00

  • Acute hepatitis A in Italy: incidence, risk factors and preventive measures.

    abstract::The incidence of, and risk factors for, acute hepatitis A (AHA) were assessed by using data collected from the Italian surveillance system of acute viral hepatitis (SEIEVA). To this end, a case-control study within a population-based surveillance for acute viral hepatitis was performed. AHA incidence has been estimate...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.01025.x

    authors: Tosti ME,Spada E,Romanò L,Zanetti A,Mele A,SEIEVA collaborating group.

    更新日期:2008-10-01 00:00:00

  • IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients.

    abstract::Hepatitis C virus (HCV) infection is associated with insulin resistance (IR), although mechanisms leading to IR in these patients are not completely understood. The aim of this study was to evaluate the association of interleukin 28B (IL28B) and interleukin 28 receptor alpha (IL28RA) polymorphisms with IR among human ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12130

    authors: Jiménez-Sousa MA,Berenguer J,Fernández-Rodríguez A,Micheloud D,Guzmán-Fulgencio M,Miralles P,Pineda-Tenor D,García-Álvarez M,López JC,Aldámiz-Echevarria T,Carrero A,Resino S

    更新日期:2014-03-01 00:00:00

  • Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research.

    abstract::Hepatitis C (HCV) infection can cause cirrhosis, liver cancer and death in the absence of treatment. Many people living in the UK but born overseas are believed to be infected with HCV although many are unlikely to know they are infected. The aim of this study is to assess the potential for a case-finding approach to ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12190

    authors: Miners AH,Martin NK,Ghosh A,Hickman M,Vickerman P

    更新日期:2014-01-01 00:00:00

  • The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.

    abstract::Peginterferon alpha-2a (40 kDa) plus ribavirin is effective at achieving sustained viral response compared with no treatment in patients with chronic hepatitis C (CHC) and persistently normal aminotransferase levels (PNALT). The cost-effectiveness of treating CHC in the setting of PNALT has not been assessed. Disease ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2005.00700.x

    authors: Hornberger J,Farci P,Prati D,Zeuzem S,Green J,Patel KK

    更新日期:2006-06-01 00:00:00

  • Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.

    abstract::Hepatitis C virus (HCV) is commonly transmitted by intravenous drug use (IDU) but drug users are under represented in many treatment cohorts, this is because of the assumption of lowered treatment success. We assessed HCV treatment outcomes in active intravenous drug users and patients on opiate substitution therapy. ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01446.x

    authors: Jafferbhoy H,Miller MH,Dunbar JK,Tait J,McLeod S,Dillon JF

    更新日期:2012-02-01 00:00:00

  • Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection.

    abstract::In rare cases, individuals with a history of long-term injecting drug use remain seronegative and aviraemic, despite prolonged and likely repeated exposure to Hepatitis C virus (HCV) through high-risk behaviour. We describe anti-HCV Envelope (E) antibody responses in a prospective cohort of carefully defined highly ex...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13339

    authors: Mina M,Underwood A,Eltahla A,Wu BR,Walker MR,Bull RA,Lloyd AR

    更新日期:2020-10-01 00:00:00

  • Hepatitis E virus infection among animals in northern India: an unlikely source of human disease.

    abstract::Hepatitis E virus (HEV) is a major cause of acute hepatitis in many developing countries. Based on data from nonendemic regions, an animal reservoir of HEV has been proposed; however, data from HEV-endemic regions are limited. We tested sera from 200 pigs, 98 chickens, 86 goats, 58 sheep and 30 buffaloes for anti-HEV ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00815.x

    authors: Shukla P,Chauhan UK,Naik S,Anderson D,Aggarwal R

    更新日期:2007-05-01 00:00:00

  • Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation.

    abstract::Through molecular virological testing it is now clear that HCV reinfection of the allograft is virtually universal in liver transplant recipients. Although histopathological recurrence of hepatitis C occurs in the majority of patients, it is absent in a substantial minority. To date, no prognostic factors, other than ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.1997.tb00172.x

    authors: Vierling JM,Villamil FG,Rojter SE,Camacho KB,Goldman DE

    更新日期:1997-01-01 00:00:00

  • Occult hepatitis C virus infection in type II mixed cryoglobulinaemia.

    abstract::Mixed cryoglobulinaemia, when not secondary to other well-defined immunological disorders, is commonly associated with hepatitis C virus (HCV) infection. However, a minority of cases lack evidence of HCV infection and are, therefore, defined as 'true essential' mixed cryoglobulinaemias. We thoroughly investigated thre...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00462.x

    authors: Casato M,Lilli D,Donato G,Granata M,Conti V,Del Giudice G,Rivanera D,Scagnolari C,Antonelli G,Fiorilli M

    更新日期:2003-11-01 00:00:00